STK33 and cancer: Bufalin (HuaChansu) was approved for cancer treatment, and several clinical investigations have recently demonstrated that it exerts anti‐cancer effects.[8] Compelling evidence shows that Bufalin exerts antitumor effects by activating apoptosis, cell cycle arrest, and suppressing angiogenesis in diverse cancer cells.[30] Here, we found that Bufalin inhibited TNBC by binding to STK33 and promoting its degradation.